The US Food and Drug Administration (FDA) has approved the sale of Bruno Vision Care’s Deseyne contact lenses, which incorporate FusionTechnology, in the American market.
The lenses integrate the patented FusionTechnology delivery system and vifilcon C, an “enriched” hydrogel material.
Go deeper with GlobalData
Bruno Vision noted that during production, bioactive substances called Lachryceuticals, including amino acids, polysaccharides, and vitamins, are said to be “embedded” within the lens’s matrix.
Leveraging the controlled-release technology, these substances are then slowly released from the lens into the eye’s anterior segment, ensuring the substances’ bioavailability throughout the wear time.
The lenses are claimed to be the only ones available globally that release hydration directly from the lens matrix.
FusionTechnology combines hyaluronic acid with tamarind seed polysaccharides, forming a bio-copolymer similar to natural tears.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis substance is gradually released, responding to body temperature, eyelid pressure, and blinking, and enhances the eye’s tear film for better hydration and comfort.
With the support of an “experienced” management team and a medical advisory board, the company is set to introduce the lenses to the US market.
Bruno Vision Care anticipates that consumers will have access to the lenses by the last quarter of this year.
Bruno Vision Care CEO Eddie Catalfamo said: “With our patented FusionTechnology proprietary manufacturing process and the novel vifilcon C material, we’re setting a new standard in vision health.
“The result is a lens that allows more people to wear contacts comfortably, provides existing wearers with greater hydration and clearer vision, and makes fitting easier for eye care professionals.
“Bringing this breakthrough to the US market has been our mission for many years, and we could not have achieved this without the hard work and determination of our US and Italian teams.”
The company was established in 2019 as a division of Italy-based Bruno Farmaceutici.
